JP2019502360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502360A5 JP2019502360A5 JP2018516122A JP2018516122A JP2019502360A5 JP 2019502360 A5 JP2019502360 A5 JP 2019502360A5 JP 2018516122 A JP2018516122 A JP 2018516122A JP 2018516122 A JP2018516122 A JP 2018516122A JP 2019502360 A5 JP2019502360 A5 JP 2019502360A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- nos
- mhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021201297A JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265615P | 2015-12-10 | 2015-12-10 | |
| US62/265,615 | 2015-12-10 | ||
| GBGB1521746.6A GB201521746D0 (en) | 2015-12-10 | 2015-12-10 | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB1521746.6 | 2015-12-10 | ||
| PCT/EP2016/078718 WO2017097602A1 (en) | 2015-12-10 | 2016-11-24 | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021201297A Division JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502360A JP2019502360A (ja) | 2019-01-31 |
| JP2019502360A5 true JP2019502360A5 (enExample) | 2020-01-30 |
| JP7053457B2 JP7053457B2 (ja) | 2022-04-12 |
Family
ID=55274485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516122A Expired - Fee Related JP7053457B2 (ja) | 2015-12-10 | 2016-11-24 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2021201297A Pending JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021201297A Pending JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (25)
| Country | Link |
|---|---|
| US (14) | US10064928B2 (enExample) |
| EP (1) | EP3387008A1 (enExample) |
| JP (2) | JP7053457B2 (enExample) |
| KR (1) | KR20180086190A (enExample) |
| CN (1) | CN108602867A (enExample) |
| AR (1) | AR106920A1 (enExample) |
| AU (3) | AU2016368981B2 (enExample) |
| BR (1) | BR112018007206A2 (enExample) |
| CA (1) | CA3005813A1 (enExample) |
| CL (6) | CL2018001532A1 (enExample) |
| CO (1) | CO2018004865A2 (enExample) |
| CR (6) | CR20200595A (enExample) |
| EA (1) | EA201891074A1 (enExample) |
| GB (1) | GB201521746D0 (enExample) |
| HK (1) | HK1259376A1 (enExample) |
| IL (1) | IL259304A (enExample) |
| MA (2) | MA43399A (enExample) |
| MX (1) | MX2018005372A (enExample) |
| PE (1) | PE20181075A1 (enExample) |
| PH (1) | PH12018500848A1 (enExample) |
| SG (3) | SG10202005498VA (enExample) |
| TW (2) | TWI658050B (enExample) |
| UA (1) | UA124575C2 (enExample) |
| WO (1) | WO2017097602A1 (enExample) |
| ZA (1) | ZA201801752B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10988543B2 (en) | 2015-11-11 | 2021-04-27 | Opi Vi—Ip Holdco Llc | Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
| CR20190509A (es) | 2017-04-10 | 2020-01-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN108079285B (zh) * | 2018-02-06 | 2021-01-01 | 昆明龙津药业股份有限公司 | 用于蛇毒酶制剂的门冬氨酸稳定剂及制备方法 |
| US11464800B2 (en) | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| CN114303060A (zh) | 2019-06-06 | 2022-04-08 | 伊玛提克斯生物技术有限公司 | 使用序列相似肽进行反向选择分选 |
| CN114174323B (zh) * | 2019-07-05 | 2025-01-07 | 弗朗西斯·克里克研究所有限公司 | 新的癌抗原和方法 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| IL295891A (en) | 2020-02-24 | 2022-10-01 | Immatics Us Inc | Methods for propagating t cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| EP4136100A4 (en) * | 2020-04-14 | 2024-08-07 | Université de Montréal | Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof |
| EP3907284A1 (en) * | 2020-05-06 | 2021-11-10 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and combinations of peptides for use in immunotherapy against hematologic neoplasms and other cancers |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2024223849A1 (en) * | 2023-04-27 | 2024-10-31 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Neoepitope immunogenic peptides for cancer treatment and diagnosis |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026033136A1 (en) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Advanced treatment modalities for anti-prame tcr-engineered immune cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029193A2 (en) | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
| US20040005561A1 (en) * | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20040000556A1 (en) * | 2003-01-25 | 2004-01-01 | Harris Jennifer Hope | Trash receptacles that use plastic grocery bags as liners and methods of advertising |
| CA2527916A1 (en) | 2003-03-14 | 2004-09-30 | Aaron B. Kantor | Biological markers for diagnosing rheumatoid arthritis |
| WO2005076009A2 (en) * | 2004-01-28 | 2005-08-18 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumour-associated peptides |
| WO2012079878A2 (en) * | 2010-12-14 | 2012-06-21 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| PL1642905T3 (pl) * | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy |
| US7608413B1 (en) * | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| US20070292869A1 (en) | 2006-03-02 | 2007-12-20 | Ppd Biomarker Discovery Sciences, Llc | Compositions and Methods for Analyzing Renal Cancer |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2009059011A2 (en) * | 2007-11-01 | 2009-05-07 | Mayo Foundation For Medical Education And Research | Hla-dr binding peptides and their uses |
| PL2119726T5 (pl) * | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| WO2010002911A2 (en) | 2008-06-30 | 2010-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods and materials for monitoring myeloma using quantitative mass spetrometry |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| WO2011027308A1 (en) | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| WO2011027311A2 (en) * | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| EP2330122A1 (en) * | 2009-12-02 | 2011-06-08 | Asklepios Kliniken Hamburg Gmbh | OFA/iLRP derived modified peptide |
| WO2011073905A1 (en) * | 2009-12-14 | 2011-06-23 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201014033D0 (en) * | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| WO2013019634A1 (en) | 2011-07-29 | 2013-02-07 | University Of Georgia Research Foundation, Inc. | Alpha toxin detection of gpi anchored proteins |
| WO2013037972A1 (en) * | 2011-09-16 | 2013-03-21 | Pamgene B.V. | Method for predicting response to endocrine therapy |
| US9500651B2 (en) * | 2012-08-15 | 2016-11-22 | Université de Montréal | Method for identifying novel minor histocompatibility antigens |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| HRP20202019T1 (hr) * | 2015-07-01 | 2021-04-30 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
-
2015
- 2015-12-10 GB GBGB1521746.6A patent/GB201521746D0/en not_active Ceased
-
2016
- 2016-11-24 KR KR1020187013544A patent/KR20180086190A/ko not_active Withdrawn
- 2016-11-24 CR CR20200595A patent/CR20200595A/es unknown
- 2016-11-24 SG SG10202005498VA patent/SG10202005498VA/en unknown
- 2016-11-24 PE PE2018000324A patent/PE20181075A1/es unknown
- 2016-11-24 CR CR20180295A patent/CR20180295A/es unknown
- 2016-11-24 CA CA3005813A patent/CA3005813A1/en not_active Abandoned
- 2016-11-24 AU AU2016368981A patent/AU2016368981B2/en not_active Ceased
- 2016-11-24 SG SG10202111398UA patent/SG10202111398UA/en unknown
- 2016-11-24 BR BR112018007206-0A patent/BR112018007206A2/pt not_active IP Right Cessation
- 2016-11-24 CN CN201680071930.3A patent/CN108602867A/zh active Pending
- 2016-11-24 CR CR20200594A patent/CR20200594A/es unknown
- 2016-11-24 CR CR20200593A patent/CR20200593A/es unknown
- 2016-11-24 HK HK19101744.6A patent/HK1259376A1/zh unknown
- 2016-11-24 MA MA043399A patent/MA43399A/fr unknown
- 2016-11-24 JP JP2018516122A patent/JP7053457B2/ja not_active Expired - Fee Related
- 2016-11-24 UA UAA201803219A patent/UA124575C2/uk unknown
- 2016-11-24 MX MX2018005372A patent/MX2018005372A/es unknown
- 2016-11-24 EA EA201891074A patent/EA201891074A1/ru unknown
- 2016-11-24 CR CR20200596A patent/CR20200596A/es unknown
- 2016-11-24 SG SG11201801670YA patent/SG11201801670YA/en unknown
- 2016-11-24 CR CR20200592A patent/CR20200592A/es unknown
- 2016-11-24 EP EP16805348.6A patent/EP3387008A1/en not_active Withdrawn
- 2016-11-24 MA MA42072A patent/MA42072A1/fr unknown
- 2016-11-24 WO PCT/EP2016/078718 patent/WO2017097602A1/en not_active Ceased
- 2016-12-06 AR ARP160103738A patent/AR106920A1/es not_active Application Discontinuation
- 2016-12-09 US US15/374,054 patent/US10064928B2/en active Active
- 2016-12-09 US US15/375,070 patent/US10398766B2/en active Active
- 2016-12-09 TW TW105140762A patent/TWI658050B/zh not_active IP Right Cessation
- 2016-12-09 US US15/374,480 patent/US10117916B2/en active Active
- 2016-12-09 TW TW108109253A patent/TWI730306B/zh not_active IP Right Cessation
-
2018
- 2018-03-14 ZA ZA2018/01752A patent/ZA201801752B/en unknown
- 2018-04-20 PH PH12018500848A patent/PH12018500848A1/en unknown
- 2018-05-08 CO CONC2018/0004865A patent/CO2018004865A2/es unknown
- 2018-05-13 IL IL259304A patent/IL259304A/en unknown
- 2018-06-08 CL CL2018001532A patent/CL2018001532A1/es unknown
- 2018-08-03 US US16/054,503 patent/US11083784B2/en not_active Expired - Fee Related
- 2018-08-22 US US16/109,451 patent/US10335474B2/en active Active
- 2018-08-22 US US16/109,427 patent/US10238725B2/en active Active
- 2018-08-22 US US16/109,406 patent/US10238724B2/en active Active
- 2018-08-22 US US16/109,436 patent/US10238726B2/en active Active
-
2019
- 2019-05-17 US US16/415,671 patent/US10653762B2/en active Active
- 2019-05-17 US US16/415,655 patent/US10653761B2/en active Active
- 2019-10-31 US US16/669,622 patent/US10722566B2/en active Active
-
2020
- 2020-07-30 CL CL2020001985A patent/CL2020001985A1/es unknown
- 2020-07-30 CL CL2020001986A patent/CL2020001986A1/es unknown
- 2020-07-30 CL CL2020001988A patent/CL2020001988A1/es unknown
- 2020-07-30 CL CL2020001989A patent/CL2020001989A1/es unknown
- 2020-07-30 CL CL2020001987A patent/CL2020001987A1/es unknown
- 2020-12-03 AU AU2020281108A patent/AU2020281108B2/en not_active Ceased
-
2021
- 2021-05-14 US US17/320,854 patent/US11260115B1/en active Active
- 2021-12-11 JP JP2021201297A patent/JP2022058349A/ja active Pending
-
2022
- 2022-01-31 AU AU2022200616A patent/AU2022200616A1/en not_active Abandoned
- 2022-02-04 US US17/665,117 patent/US20220226450A1/en not_active Abandoned
-
2024
- 2024-04-26 US US18/647,775 patent/US20240285738A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502360A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2021168652A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2018511321A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| JP2018519243A5 (enExample) | ||
| JP2018518937A5 (enExample) | ||
| JP2018509135A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2024099580A5 (enExample) | ||
| JP2018521641A5 (enExample) | ||
| JP2017525336A5 (enExample) | ||
| JP2018518956A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2020530759A5 (enExample) | ||
| JP2017524337A5 (enExample) | ||
| JP2019516663A5 (enExample) | ||
| AR106920A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
| JP2020516681A5 (enExample) |